p-Heptylzimtsaeure | 57045-20-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: p-Heptylzimtsaeure
• 英文别名: p-n-Heptylcinnamic acid；3-(4-heptylphenyl)prop-2-enoic acid
• CAS: 57045-20-2
• 化学式: C₁₆H₂₂O₂
• 分子量: 246.349
• InChiKey: CQKKAIGLUZJBPG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  p-Heptylzimtsaeure 在 氯化亚砜 作用下， 生成 3-(4-Heptylphenyl)prop-2-enoyl chloride
  参考文献：
  名称：

  Bykova, V. V.; Zharova, M. A.; Maidachenko, G. G., Russian Journal of Organic Chemistry, 1996, vol. 32, # 8, p. 1143 - 1145

  摘要：

  DOI：
• 作为产物：
  描述：

  庚基苯 在 哌啶 、 吡啶 作用下， 生成 p-Heptylzimtsaeure
  参考文献：
  名称：

  Pavlyuchenko,A.I. et al., Journal of Organic Chemistry USSR (English Translation), 1976, vol. 12, # 2, p. 369 - 372

  摘要：

  DOI：

文献信息

• Tyrosine phosphatase inhibitors
  申请人：——

  公开号：US20030144338A1

  公开（公告）日：2003-07-31

  A compound of the formula (I): 1 wherein X 1 and X 2 are the same or different and each is a bond or a spacer having 1 to 20 atom(s) in the main chain; one of R 1 and R 2 is a cycle group having substituent(s) selected from 1) an optionally substituted carboxy-C 1-6 alkoxy group and 2) an optionally substituted carboxy-C 1-6 aliphatic hydrocarbon group, wherein the cycle group optionally has additional substituent(s), and the other is an optionally substituted cycle group or a hydrogen atom; and R 3 , R 4 and R 5 are the same or different and each is a hydrogen atom or a substituent, or R 4 may link together with R 3 or R 5 to form an optionally substituted ring; provided that when R 3 is a hydrogen atom, R 4 is a hydrogen atom and R 5 is methyl, X 2 —R 2 is not 4-cyclohexylphenyl; when R 3 is 4-methoxyphenyl, R 4 is a hydrogen atom and R 5 is methyl, X 2 —R 2 is not 4-methoxyphenyl; and when R 1 or R 2 is a hydrogen atom, the adjacent X 1 or X 2 is not a C 1-7 alkylene; or a salt thereof exhibits a protein tyrosine phosphatase inhibitory action and is useful as a prophylactic or therapeutic agent for diabetes or the like.

  式（I）的化合物： 其中X1和X2相同或不同，每个都是主链中具有1至20个原子的键或间隔物； R1和R2中的一个是具有取代基的环基，所述取代基选自1）可选择地取代的羧基-C1-6烷氧基和2）可选择地取代的羧基-C1-6脂肪烃基，其中所述环基可选择地具有额外的取代基，另一个是可选择地取代的环基或氢原子；以及 R3、R4和R5相同或不同，每个是氢原子或取代基，或R4可以与R3或R5结合形成可选择地取代的环； 但是当R3是氢原子时，R4是氢原子且R5是甲基时，X2—R2不是4-环己基苯基；当R3是4-甲氧基苯基，R4是氢原子且R5是甲基时，X2—R2不是4-甲氧基苯基；当R1或R2是氢原子时，相邻的X1或X2不是C1-7烷基； 或其盐具有蛋白酪氨酸磷酸酶抑制作用，并且可用作糖尿病等疾病的预防或治疗剂。
• REACTIVE PERPENDICULAR ALIGNED MATERIAL, LIQUID CRYSTAL DISPLAY PANEL, AND METHOD OF LIQUID CRYSTAL ALIGNMENT
  申请人：Shenzhen China Star Optoelectronics Technology Co., Ltd.

  公开号：US20180030352A1

  公开（公告）日：2018-02-01

  The disclosure provides a reactive perpendicular aligned material, a liquid crystal display panel, and a method for aligning liquid crystals, a general structural formula of the reactive perpendicular aligned material is A-Z—R, A is —CH═CH—COOH; Z is where n≧1; R represents a linear chained or a branched chained alkyl group with 5˜20 C atoms, a CH 2 group in the alkyl group is substituted by a phenyl group, a naphthenic base, —CONH—, —COO—, —O—CO—, —S—, —CO— or —CH═CH—, or a F atom or a Cl atom substitutes for a H atom in the alkyl group. A head group A plays a role in anchoring, it can be anchored on a surface of a substrate utilizing the —COOH group by means of physical reaction, meanwhile, it can strengthen the ability of anchoring liquid crystal molecules by the reaction of a —CH═CH— group and a reactive monomer

  本公开提供了一种反应性垂直排列材料、液晶显示面板和液晶对准方法，其中反应性垂直排列材料的一般结构式为A-Z—R，其中A是—CH═CH—COOH；Z是n≧1；R表示具有5˜20个C原子的线性链或支链烷基，烷基中的一个CH2基团被苯基、萘基、—CONH—、—COO—、—O—CO—、—S—、—CO—或—CH═CH—替代，或者F原子或Cl原子替代烷基中的H原子。头基A起到锚定作用，它可以通过物理反应利用—COOH基团锚定在基板表面上，同时，它可以通过—CH═CH—基团和反应单体的反应增强锚定液晶分子的能力。
• Liquid crystalline cinnamic acid esters
  申请人：Hoffmann-La Roche Inc.

  公开号：US04061587A1

  公开（公告）日：1977-12-06

  Liquid crystalline alkylcinnamic acid p'-cyanophenyl esters, useful, for example, for electro-optical purposes, are described.

  本文介绍了液晶烷基肉桂酸p'-氰基苯酯，例如用于电光目的。
• TYROSINE PHOSPHATASE INHIBITORS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1284260A1

  公开（公告）日：2003-02-19

  A compound of the formula (I):    wherein X1 and X2 are the same or different and each is a bond or a spacer having 1 to 20 atom(s) in the main chain;    one of R1 and R2 is a cycle group having substituent(s) selected from 1) an optionally substituted carboxy-C1-6 alkoxy group and 2) an optionally substituted carboxy-C1-6 aliphatic hydrocarbon group, wherein the cycle group optionally has additional substituent(s), and the other is an optionally substituted cycle group or a hydrogen atom; and    R3, R4 and R5 are the same or different and each is a hydrogen atom or a substituent, or R4 may link together with R3 or R5 to form an optionally substituted ring;    provided that when R3 is a hydrogen atom, R4 is a hydrogen atom and R5 is methyl, X2-R2 is not 4-cyclohexylphenyl; when R3 is 4-methoxyphenyl, R4 is a hydrogen atom and R5 is methyl, X2-R2 is not 4-methoxyphenyl; and when R1 or R2 is a hydrogen atom, the adjacent X1 or X2 is not a C1-7 alkylene; or a salt thereof exhibits a protein tyrosine phosphatase inhibitory action and is useful as a prophylactic or therapeutic agent for diabetes or the like.

  式(I)化合物： 其中 X1 和 X2 相同或不同，且各自为键或在主链中具有 1 至 20 个原子的间隔物； R1 和 R2 中的一个是具有选自 1）任选取代的羧基-C1-6 烷氧基和 2）任选取代的羧基-C1-6 脂肪族烃基的取代基的循环基团，其中循环基团任选具有附加取代基，另一个是任选取代的循环基团或氢原子；以及 R3、R4 和 R5 相同或不同，且各自为氢原子或取代基，或 R4 可与 R3 或 R5 连接形成任选取代的环； 条件是当 R3 是氢原子、R4 是氢原子且 R5 是甲基时，X2-R2 不是 4-环己基苯基；当 R3 是 4-甲氧基苯基、R4 是氢原子且 R5 是甲基时，X2-R2 不是 4-甲氧基苯基；以及当 R1 或 R2 是氢原子时，相邻的 X1 或 X2 不是 C1-7 亚烷基； 或其盐具有蛋白酪氨酸磷酸酶抑制作用，可用作糖尿病或类似疾病的预防或治疗剂。
• US4061587A
  申请人：——

  公开号：US4061587A

  公开（公告）日：1977-12-06